



List of candidates proposed for the election of the Executive Committee of the 18th legislative periode

International Association for Pharmaceutical Technology
Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V.
Gemeinnütziger wissenschaftlicher Verein

2022-2026

List of candidates proposed for the election of the Executive Committee of the 18th legislative periode

Persons

Prof. Dr. Johannes Bartholomäus

TU Braunschweig and
Pharmakreativ Pharmaceutical Development
Consulting
Burghöhenweg 5
52080 Aachen
Germany

Prof. Dr. Sandra Klein

Institut für Pharmazie
Biopharmazie und Pharmazeutische Technologie
Universität Greifswald
Center of Drug Absorption and Transport
Felix-Hausdorff-Strasse 3
17489 Greifswald
Germany

Dr. Kathrin Bartscher

NextPharma
Hildebrandstr. 12
37081 Göttingen
Germany

Dr. Martin Lück

Grünenthal GmbH
Zieglerstraße 6
52078 Aachen
Germany

Dr. Karoline Bechtold-Peters

Novartis Pharma AG
4002 Basel
Werk Klybeck
Switzerland

Dr. Florian Unger

Bayer AG
Friedrich-Ebert-Str. 217
42117 Wuppertal
Germany

Prof. Dr. Jörg Breitzkreutz

Heinrich Heine University Düsseldorf
Institute of Pharmaceutics and
Biopharmaceutics
Universitätstr. 1
40225 Düsseldorf
Germany

Dr. Alena Wieber

Merck Healthcare KGaA
Frankfurter Str. 250
64293 Darmstadt, Germany



Prof. Dr. Johannes Bartholomäus
born 1959
in Lohne i.O.
Germany

Prof. Dr. Johannes (Hans) Bartholomäus studied Pharmacy (1979-1983) at the TU Braunschweig, Germany, followed by the practical year in the Adler Apotheke, Borken, and Kettelhack Riker Pharma, Borken (1983-1984). He finished his thesis at the Institute of Pharmaceutical Technology of TU Braunschweig under the supervision of Prof. Dr. C. Führer (1988). Hans started his industrial career at Grünenthal GmbH as Head of the Solid Oral Dosage Forms Lab and from 1992 to 2008 he was heading Pharmaceutical Development of Grünenthal. In 2009 Hans started his own Pharmaceutical Development Consultancy. Besides, he is an invited lecturer (since 2001) for Industrial Pharmacy and Honorary Professor (2009) at TU Braunschweig. Currently he is teaching pharmaceutical quality system for Master of Pharmaengineering. His special professional interests are Drug Delivery, Life Cycle Management, IP Management, Quality Systems, Drug Stability, Clinical Supplies and Pharmaceutical Development Strategies including Quality by Design.

Hans became member of APV during his Ph.D. studies mid of the 1980ies. He was a co-founding member of APV's Drug Delivery Focus Group in 2003 and became chairman of this group from 2014 to 2018. He was member of the program committees of the 1st European Conference on Pharmaceutics in Reims (2015) and the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology in Granada (2018). Since 2018 he is a member of the Board of APV.

Objectives:

- Strengthen internationalization of APV and making APV visible as the European platform for Pharmaceutics, Biopharmaceutics and Pharmaceutical Technologists in Academia, Regulatory Bodies and Industry
- Grow networking opportunities for members and participants and increase value of APV membership
- Improve quality of APV processes and standards



Dr. Kathrin Bartscher
born 1978
in Brilon
Germany

Dr. Kathrin Bartscher studied Pharmacy at the Westphalian Wilhelms-University of Muenster (Germany). After finishing her doctoral thesis at the Institute for Pharmaceutical Technology and Biopharmaceutics in Muenster under supervision of Prof. Dr. R. Gröning in 2006 she joined NextPharma as formulation scientist. In 2013 she was appointed as Head of Drug Product Development at the NextPharma site in Waltrop. 2016 she took over the global responsibility for the development activities at all NextPharma sites and joined the NextPharma board in July 2017 as Chief Scientific Officer.

She was initiator of the first APV local in Dortmund. Since 2014 she is member of the APV board and treasurer of APV.

Objectives:

- Develop and re-emphasize APV membership value to keep existing members and gain new members from academia and industry in challenging times of price pressure increase
- Further improve the visibility and perception of APV in the market after two years of focus on minimizing covid-related financial damages
- Enlarge the seminar & conference program and strengthen the international and interdisciplinary focus



**Dr. Karoline
Bechtold-Peters**
born 1964
in Munich
Germany

Dr. Karoline Bechtold-Peters is pharmacist and received her doctorate from the Ludwigs-Maximilians-University of Munich in Pharmaceutical Technology in 1994 for a thesis in the field of enteric-coated pancreatin pellets. In 1994, Karoline started at Boehringer Ingelheim in Ingelheim as Head of Laboratory in Solid Dosage Forms, focusing on powder inhalation therapeutics. In this context, Karoline was instrumental in the development of the blockbuster Spiriva. In 2000, she moved to the Business Unit Biopharmaceuticals of Boehringer Ingelheim and thus to Biberach to build-up Formulation Development of Therapeutic Proteins. In 2003 she was appointed 2003 Head of Global Clinical Supplies, Aseptic Process Development and Process Transfer. After several years in this position, Karoline moved to Basel, Switzerland, in 2011, to join Hoffmann La-Roche and was assigned Head of Drug Product Clinical Supply Center Basel within Global Biologics Europe and was responsible for the production of biopharmaceutical clinical supplies both for Roche and Genentech. It became her core task to ramp up the brand new clinical lines for sterile vials and syringes covering initial inspections and initial batch production from 2011 to 2013. The expansion of the production to Antibody-Drug-Conjugates followed. In 2016, Karoline joined Novartis Pharma AG in Basel to focus on more strategic and future-looking issues of Biopharmaceuticals as Senior Strategy and Technology Leader Pharmaceutics within Biologics Technical Development & Manufacturing (BTDM) and the team "BioFuture". Since the reorganization of the Biologics business, Karoline has been part of the Scientific Offices Drug Product Development within Global Biologics & Cell and Gene Therapy as Director Science & Technology, representing the focus on Innovation and External Engagement. Karoline is member of APV since 1994. Besides this she is active in several international organisations such as EBE/EFPIA, AAPS and PDA, and is frequently invited to contribute to conferences and papers or books.

Objectives:

- Ensure that APV is on top of the relevant industry topics
- Strengthen Biopharmaceuticals and Cell and Gene Therapy within APV
- Strengthen innovative manufacturing technologies to ensure flexible supply with medication
- Connect APV increasingly to international work streams, further drive the international orientation of APV and reinforce international collaborations
- Increase the value of APV membership by addressing burning topics



**Prof. Dr. Jörg
Breitzkreutz**
born 1966
in Marl
Germany

Joerg Breitzkreutz studied Pharmacy at the Westfälische Wilhelms-University (WWU) in Münster and received his doctorate degree in pharmaceutical technology from this university in 1996 for his work on drug or excipients interactions with polyethylene glycols investigated by Molecular Modelling technologies, supervised by Dr. Georg Heun and Prof. Dr. Rüdiger Gröning. After almost 2 years of industrial experience as the Head of Product Coordination at Thiemann Arzneimittel GmbH in Waltrop, Germany (subsidiary of Organon, The Netherlands) he went back to WWU Muenster for his habilitation on "Paediatric drug formulations" which he finalized in 2004. Shortly before that, he joined the Heinrich Heine University (HHU) Düsseldorf as Professor for Pharmaceutical Technology and Biopharmaceutics. Since 2011, he is the director of the Institute of Pharmaceutics and Biopharmaceutics at HHU. His research topics include drug development for special patient populations such as children and the elderly, orphan drugs and process analytical technologies. In 2010, he became president of APV and maintained this position until today. He also serves as a German delegate and the chair of the PaedForm Working Party at the European Directorate for Quality and Healthcare (EDQM) in Strasbourg, France.

Objectives:

- Strengthen the position of APV as a globally leading academia-industry network
- Maintaining the solid financial background of APV
- Promoting the idea of Long-life learning of young scientists from experienced APV members
- Ensuring the science-based knowledge of pharmacists and other persons in pharmaceutical industry
- Enlarging the offers of APV for its members and the international pharmaceutical community



Prof. Dr. Sandra Klein
born 1970
in Büdingen
Germany

Prof. Dr. Sandra Klein studied pharmacy at the University of Frankfurt am Main, Germany. She graduated in 2000, received her PhD in 2005 and subsequently held a postdoctoral position at Eastman Chemical Company in Kingsport/TN, USA. From 2006 to 2010 she was a senior research associate at the Institute of Pharmaceutical Technology at the University of Frankfurt, Germany. In 2009, she was offered a professorship in Pharmaceutical Technology at the University of Greifswald, Germany, where she has been employed as a professor since 2010.

Her current research focuses on improving drug therapy of special patient populations, particularly pediatric patients, by developing predictive in vitro and in silico models and patient-centered formulations. Other research interests include the development of biopredictive and accelerated in vitro test methods for non-oral delivery systems as well as improving the bioavailability of poorly soluble drugs using polymer-, cyclodextrin- and micelle-based systems.

Sandra Klein has been a member of APV since 2000 and is a member of the American Association of Pharmaceutical Scientists (AAPS), the German Pharmaceutical Society (DPhG) and the European Paediatric Formulation Initiative (EuPFI), amongst others.

Objectives:

- to strengthen the APV's collaboration with other national and international societies, universities, and industry
- to bind young pharmacists to the APV, giving them the opportunity to actively participate in the activities of the APV network and to create the basis for a long-term relationship
- to continue and further expand the collaboration between academia and industry
- to further increase the visibility of the APV



Dr. Martin Lück
born 1968
in Rendsburg
Germany

Dr. Martin Lück is Senior Vice President and Head of Global Manufacturing Science & Integration (MSI) at Grünenthal GmbH, Aachen (Germany). In his current role, he oversees teams in Europe and Latin America focusing on product improvements and a group of project managers orchestrating the end-to-end integration of new products. He joined Grünenthal in 2010 as Head of Pharmaceutical Development. He was appointed Head of CMC in 2014, Head of Drug Development in 2017 and Head of MSI in 2019.

From 1998 to 2010 Dr. Lück held various leadership positions in Pharmaceutical Development and Technical Operations at Ferring Pharmaceuticals in Germany, Denmark and Switzerland.

Dr. Lück studied Pharmacy at the Christian Albrecht University Kiel. He finished his PhD thesis in Pharmaceutical Technology at the Free University of Berlin under supervision of Prof. Dr. Rainer H. Müller. He received the APV award for the most outstanding doctoral thesis in the pharmaceutical sciences in the year 1997.

Objectives:

- Strengthen interactions between APV and Pharmaceutical Industry
- Increase visibility of APV in Pharmaceutical Industry to attract new members and keep members actively involved
- Foster the interactions between APV Board and APV members
- Contribute to APV's seminar and conference programs



Dr. Florian Unger
born 1975
in Cologne
Germany

Florian Unger studied pharmacy at the Westfaelische Wilhelms-University in Muenster and received his doctorate degree in pharmaceutical technology from Philipps-University, Marburg for his work in the area of Polymeric Drug Delivery, supervised by Prof. Thomas Kissel.

He started his industrial career at Solvay Pharmaceuticals GmbH (later Abbott Products GmbH) in Hannover in 2005 as a lab head in oral formulation development, focusing on development of spray drying and formulation processes for gastric enzymes. In 2010, he joined Bayer Schering AG in Berlin as Technology Scout for Drug Delivery Technologies. Within that role, he was responsible for creating technology landscapes and setting up collaborations with academia as well as partnerships with technology companies. In addition, he co-supervised the development and market authorization of a transdermal patch. In 2014, a new role led him to the Wuppertal site of Bayer AG, where he built up capabilities in ocular and inhaled formulation development as Director for Parenteral Drug Delivery. In 2018, he took over the responsibility for Parenteral Drug Delivery capturing internal and external development of a broad range of modalities for the administration via different parenteral routes.

Since 2022, Florian Unger is responsible for Drug Product Development at Bayer Pharma, covering oral and parenteral formulation & process development, drug product analytics and clinical supply manufacturing of oral solids.

Objectives:

- Promote and strengthen the academia-industry network
- Maximize the exchange between young talents and experienced professionals
- Support building the APV brand as a go-to-organization for experts in pharmaceutical technology and industrial pharmacy
- Further Develop and promote APV as valuable organization for its members



Dr. Alena Wieber
born 1984
in Groß-Gerau
Germany

Dr. Alena Wieber studied Pharmacy at the Johann Wolfgang Goethe-University of Frankfurt (Germany). Alena holds a doctorate degree in pharmaceutical technology from the University of Frankfurt, under the guidance of Prof. Dr. J. Kreuter.

In 2011, she started her career at Merck KGaA, business unit Healthcare R&D, in parenteral drug product formulation development. In 2012, Alena changed internally into the Life Science sector and progressed into several R&D formulation development roles, including solid oral, semi-solid and innovative liquid excipient formulation development. In 2017, she transitioned into the marketing organization and took over the global role as Head of Technical Training, developing and executing customer hands-on programs worldwide. Since January 2021, Alena is working in the Alliance Management and Business Development sector, responsible for scouting, evaluation, negotiation and maintaining strategic partnerships by identification and development of additional pharmaceutical opportunities for the Merck Life Science Process Solutions business.

Objectives:

- Broaden the international pharmaceutical network and collaboration by extension and connection of key industrial pharma stakeholders to the APV
- Increase the visibility of APV in the pharmaceutical industry
- Motivate new members to join and active participation of APV initiatives



MAKING SCIENCE WORK

International Association for Pharmaceutical Technology
Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V.
Gemeinnütziger wissenschaftlicher Verein

APV
Kurfürstenstraße 59
55118 Mainz/Germany



+49 6131 9769-0



+49 6131 9769-69



apv@apv-mainz.de



www.apv-mainz.de